Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2013, Article ID 204649, 5 pages
http://dx.doi.org/10.1155/2013/204649
Clinical Study

S-Adenosyl-L-Methionine Augmentation in Patients with Stage II Treatment-Resistant Major Depressive Disorder: An Open Label, Fixed Dose, Single-Blind Study

1Chair of Psychiatry, Department of Neurosciences and Imaging, University “G. d’Annunzio”, 66100 Chieti, Italy
2National Health Service (NHS), Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, p.zza Italia 1, ASL 4, 64100 Teramo, Italy
3Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics, Section of Psychiatry, Department of Neuroscience, University School of Medicine “Federico II”, 80131 Naples, Italy
4Hermanas Hospitalarias, FoRiPsi, Villa S. Giuseppe Hospital, 63100 Ascoli Piceno, Italy
5Institute of Psychiatry, University of Catania, 95121 Catania, Italy
6Hermanas Hospitalarias, FoRiPsi, Department of Clinical Neurosciences, Villa San Benedetto Menni, Albese con Cassano, Como, Italy
7Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine, University of Miami, Miami, 33124 FL, USA
8Department of Psychiatry and Neuropsychology, University of Maastricht, 6200 MD Maastricht, The Netherlands

Received 15 March 2013; Accepted 18 April 2013

Academic Editors: I. Ahmed (Ike) and S. C. Bhatia

Copyright © 2013 Domenico De Berardis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Kessler, P. Berglund, O. Demler et al., “The epidemiology of major depressive disorder: results from the national comorbidity survey replication (NCS-R),” The Journal of the American Medical Association, vol. 289, no. 23, pp. 3095–3105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Fava, “Diagnosis and definition of treatment-resistant depression,” Biological Psychiatry, vol. 53, no. 8, pp. 649–659, 2003. View at Publisher · View at Google Scholar
  3. M. B. Keller, “Issues in treatment-resistant depression,” The Journal of Clinical Psychiatry, vol. 66, supplement 8, pp. 5–12, 2005. View at Publisher · View at Google Scholar
  4. M. E. Thase and A. J. Rush, “Treatment-resistant depression,” in Psychopharmacology: The Fourth Generation of Progress, F. E. Bloom and D. J. Kupfer, Eds., pp. 1081–1097, Raven Press, New York, NY, USA, 1995. View at Google Scholar
  5. H. Hori and H. Kunugi, “The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial,” The Scientific World Journal, vol. 2012, Article ID 372474, 8 pages, 2012. View at Publisher · View at Google Scholar
  6. C. S. Lieber, “S-adenosyl-L-methionine: Its role in the treatment of liver disorders,” The American Journal of Clinical Nutrition, vol. 76, no. 5, pp. 1183S–1187S, 2002. View at Google Scholar · View at Scopus
  7. S. Clarke and K. Banfield, “S-adenosylmethionine-dependent methyltransferases,” in Homocysteine in Health and Disease, R. Carmel and D. Jacobsen, Eds., pp. 63–78, Cambridge University Press, Cambridge, UK, 2001. View at Google Scholar
  8. J. D. Finkelstein, W. E. Kyle, J. J. Martin, and A. M. Pick, “Activation of cystathionine synthase by adenosylmethionine and adenosylethionine,” Biochemical and Biophysical Research Communications, vol. 66, no. 1, pp. 81–87, 1975. View at Google Scholar · View at Scopus
  9. M. L. Cravo, L. M. Gloria, J. Selhub et al., “Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status,” The American Journal of Clinical Nutrition, vol. 63, no. 2, pp. 220–224, 1996. View at Google Scholar · View at Scopus
  10. T. Bottiglieri, M. Laundy, and R. Martin, “S-adenosylmethionine influences monoamine metabolism,” The Lancet, vol. 2, no. 8396, p. 224, 1984. View at Google Scholar · View at Scopus
  11. G. I. Papakostas, C. F. Cassiello, and N. Iovieno, “Folates and S-adenosylmethionine for major depressive disorder,” Canadian Journal of Psychiatry, vol. 57, no. 7, pp. 406–413, 2012. View at Google Scholar
  12. J. E. Alpert, G. Papakostas, D. Mischoulon et al., “S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxine,” Journal of Clinical Psychopharmacology, vol. 24, no. 6, pp. 661–664, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. G. I. Papakostas, D. Mischoulon, I. Shyu, J. E. Alpert, and M. Fava, “S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial,” The American Journal of Psychiatry, vol. 167, no. 8, pp. 942–948, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Berlanga, H. A. Ortega-Soto, M. Ontiveros, and H. Senties, “Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine,” Psychiatry Research, vol. 44, no. 3, pp. 257–262, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. M. B. First, R. L. Spitzer, M. Gibbon, and J. B. W. Williams, Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version (SCID-I/P), Biometrics Research, New York, NY, USA, 2002.
  16. M. Hamilton, “A rating scale for depression,” Journal of Neurology, Neurosurgery, and Psychiatry, vol. 23, pp. 56–62, 1960. View at Google Scholar · View at Scopus
  17. W. Guy and Clinical Global Impression, ECDEU Assessment Manual for Psychopharmacology, National Institute of Mental Health, Rockville, Md, USA, 1976.
  18. R. P. Snaith, M. Hamilton, S. Morley, A. Humayan, D. Hargreaves, and P. Trigwell, “A scale for the assessment of hedonic tone. The Snaith-Hamilton pleasure scale,” The British Journal of Psychiatry, vol. 167, pp. 99–103, 1995. View at Google Scholar · View at Scopus
  19. J. C. Ballenger, “Clinical guidelines for establishing remission in patients with depression and anxiety,” Journal of Clinical Psychiatry, vol. 60, pp. 29–34, 1999. View at Publisher · View at Google Scholar
  20. M. Fava, A. J. Rush, S. R. Wisniewski et al., “A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report,” The American Journal of Psychiatry, vol. 163, no. 7, pp. 1161–1172, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Fang, C. Yuan, Y. Xu et al., “A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression,” Journal of Clinical Psychopharmacology, vol. 31, no. 5, pp. 638–642, 2011. View at Publisher · View at Google Scholar
  22. F. Gambi, D. de Berardis, D. Campanella et al., “Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study,” Journal of Psychopharmacology, vol. 19, no. 5, pp. 483–487, 2005. View at Publisher · View at Google Scholar · View at Scopus